Laidlaw downgraded Repros Therapeutics (NASDAQ: RPRX) from Buy to Neutral.Analyst Dr. Yale Jen is disappointed with the FDA's prelim feedback ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE